Journal Home
Search for

Volume 6, Issue 9, Pages 3379-3387 (September 2010)


View previous. 4 of 51 View next.

Octacalcium phosphate: Osteoconductivity and crystal chemistry

O. SuzukiCorresponding Author Informationemail address

Received 25 January 2010; received in revised form 31 March 2010; accepted 1 April 2010. published online 05 April 2010.

Abstract 

Octacalcium phosphate (OCP), which is structurally similar to hydroxyapatite (HA), is a possible precursor of bone apatite crystals. Although disagreement remains as to whether OCP comprises the initial mineral crystals in the early stage of bone mineralization, the results of recent biomaterial studies using synthetic OCP indicate the potential role of OCP as a bone substitute material, owing to its highly osteoconductive and biodegradable characteristics. OCP tends to convert to HA not only in an in vitro environment, but also as an implant in bone defects. Several lines of evidence from both in vivo and in vitro studies suggest that the conversion process could be involved in the stimulatory capacity of OCP for osteoblastic differentiation and osteoclast formation. However, the osteoconductivity of OCP cannot always be secured if an OCP with distinct crystal characteristics is used, because the stoichiometry and microstructure of OCP crystals greatly affect bone-regenerative properties. Osteoconductivity and stimulatory capabilities may be caused by the chemical characteristics of OCP, which allows the release or exchange of calcium and phosphate ions with the surrounding of this salt, and its tendency to grow towards specific crystal faces, which could be a variable of the synthesis condition. This paper reviews the effect of calcium phosphates on osteoblastic activity and bone regeneration, with a special emphasis on OCP, since OCP seems to be performing better than other calcium phosphates in vivo.

Division of Craniofacial Function Engineering, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan

Corresponding Author InformationTel.: +81 22 717 7635; fax: +81 22 717 7637.

PII: S1742-7061(10)00180-7

doi:10.1016/j.actbio.2010.04.002


View previous. 4 of 51 View next.